Skip to main content

Table 2 Multivariable adjusted risks of CVD and hard CVD based on different glucose intolerance categories. (n = 408)

From: Long term prognostic implication of newly detected abnormal glucose tolerance among patients with stable cardiovascular disease: a population-based cohort study

  CVD HR (95%CI) Hard CVD HR (95%CI)
E/N Model 1 Model 2 E/N Model 1 Model 2
FPG-WHO (mmol/L)
  < 6.1 169/327 1.00 1.00 66/327 1.00 1.00
 6.1–6.9 21/44 0.92 (0.58–1.45) 0.87 (0.55–1.39) 10/44 1.13 (0.58–2.21) 0.97 (0.49–1.93)
  ≥ 7 30/37 2.02 (1.36–3.00) 2.07 (1.39–3.12) 13/37 1.95 (1.07–3.53) 2.02 (1.07–3.80)
FPG-ADA (mmol/L)
  < 5.6 129/253 1.00 1.00 45/253 1.00 1.00
 5.6–6.9 61/118 1.07 (0.79–1.46) 1.05 (0.77–1.44) 31/118 1.62 (1.03–2.57) 1.52 (0.95–2.45)
  ≥ 7 30/37 2.09 (1.40–3.12) 2.15 (1.41–3.27) 13/37 2.28 (1.23–4.22) 2.41 (1.25–4.67)
2 h-PCPG (mmol/L)
  < 7.8 123/240 1.00 1.00 50/240 1.00 1.00
 7.8–11.0 54/105 1.01 (0.73–1.39) 0.97 (0.70–1.36) 20/105 0.93 (0.55–1.56) 0.90 (0.53–1.55)
  ≥ 11 43/63 1.48 (1.04–2.10) 1.46 (1.02–2.11) 19/63 1.59 (0.93–2.70) 1.54 (0.88–2.70)
  1. Model 1: age and sex
  2. Model 2: model 1+ body mass index, current smoking, family history of premature CVD, hypertension, hypercholesterolemia, low HDL-C, heart rate, use of aspirin, use of beta blockers and low physical activity.
  3. E event in the target group, N total sample size in the target group, CVD cardiovascular disease, CHD coronary heart disease, HR hazard ratio, CI confidence interval, FPG fasting plasma glucose, 2h-PCPG 2h post challenge plasma glucose, WHO World Health Organization, ADA American Diabetes Association